Medetomidine hydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的、高选择性的 α2-肾上腺素受体激动剂，Ki 为 1.08 nM；用作手术麻醉剂和镇痛剂。

A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.(In Vitro):Medetomidine (0-1 μM, 1 h) hydrochloride inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) hydrochloride activates a kicking response in Cyprids.Medetomidine (1 μM) hydrochloride increases cellular cAMP production by activating β-like receptors in CHO cells.(In Vivo):Medetomidine (200 μg/kg, p.o. or i.m.) hydrochloride induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) hydrochloride shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) hydrochloride protects against Diazinon-induced toxicosis in mice.

Medetomidine (0-1 μM, 1 h) hydrochloride inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) hydrochloride activates a kicking response in Cyprids.Medetomidine (1 μM) hydrochloride increases cellular cAMP production by activating β-like receptors in CHO cells.

Medetomidine (200 μg/kg, p.o. or i.m.) hydrochloride induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) hydrochloride shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) hydrochloride protects against Diazinon-induced toxicosis in mice. Animal Model:Diazinon (75 mg/kg, orally)-induced toxicosis in miceDosage:0.05, 0.1 and 0.3 mg/kgAdministration:Subcutaneous injection (s.c.), 15 min before Diazinon.Result:Protected the mice from the toxicity induced by Diazinon.Decreased the occurrence of Straub tail, excessive salivation and tremor. Increased the latencies to onset of tremor and death when compared with control.Animal Model:DogsDosage:20 μg/kg Administration:Intravenous injection (i.v.)Result:Showed sedative and analgesic effects.Increased in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature.

MPV-785

Angiogenesis

Adrenergic Receptor

α2-adrenoceptor

Neurological Disease

——

86347-15-1

236.7405

C13H17ClN2

>98% (HPLC)

10 mM in DMSO

CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl

1H-Imidazole, 5-[1-(2,3-dimethylphenyl)ethyl]-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years